Eli Lilly filed its second-quarter results with the SEC in July. The filing says the clinical data package for retatrutide is now complete, and that the company plans to submit a Biologics License Application to the FDA in the first quarter of 2027.[^1]
It is the first time the company has named a filing window in a regulatory filing instead of an analyst call. That makes it the closest thing to a confirmed timeline this compound has had.
If you are seeing it sold as GLP-3 or GLP-3 RT, that is the same compound.
It is also further away than it sounds. Most of the confusion about this drug sits in the gap between a filing and a prescription.
What Lilly actually said
The filing carried three pieces of information about retatrutide, and only the last of them is new.
The data package is complete for three indications: obesity, obstructive sleep apnea, and knee osteoarthritis pain. That is a broader opening label than semaglutide or tirzepatide had at launch.
Three additional phase 3 trials in obesity read out positively during the quarter, which is what completed the package.
And the filing itself is planned for the first quarter of 2027, which is the new part, appearing in a document filed with the SEC rather than a press release.
Why the three indications matter
The data package covers obesity, obstructive sleep apnea and knee osteoarthritis pain. That is a broader opening label than either drug ahead of it launched with, and the reason to care is coverage, not prestige.
Insurers treat obesity very differently from a diagnosed condition. A prescription written for weight alone is frequently refused, while the same drug for a named comorbidity is frequently paid for. That distinction decides who can actually get these drugs, and our guide on what peptide therapy costs sets out how far apart the routes are.
There is a worked example already. Tirzepatide was approved for obesity, then for obstructive sleep apnea at the end of 2024, and the second approval changed who could obtain it without changing the drug at all. Retatrutide is positioned to arrive with that breadth from the start.
Whether that translates into coverage depends on the label the FDA actually grants, which can be narrower than the application requests.
The TRIUMPH trial results so far
| Trial | Population | Headline result |
|---|---|---|
| TRIUMPH-4 (Dec 2025) | Obesity with knee osteoarthritis | 28.7% weight loss, substantial pain reduction |
| TRANSCEND-T2D-1 (Mar 2026) | Type 2 diabetes | A1C down 1.7 to 2.0%, 16.8% weight loss |
| TRIUMPH-1 (May 2026) | Obesity, no diabetes. The pivotal trial | 28.3% at 80 weeks, 2,339 participants |
| TRIUMPH-2 (Jul 2026) | Obesity with type 2 diabetes | 20.8% weight loss, A1C down up to 1.6% |
| TRIUMPH-3 (Jul 2026) | Obesity with established cardiovascular disease | 22.6% weight loss |
Two rows are worth pausing on.
The pivotal obesity result held at scale. Phase 2 reported 24.2% at 48 weeks in 338 people, and the number people quote from that trial is usually the completer figure and not the intention-to-treat one.[^2] TRIUMPH-1 reported 28.3% at 80 weeks across 2,339 participants, which is a larger effect in a much larger trial.[^3] As of 29 September, the pivotal trial is now published in the New England Journal of Medicine, and the figures held.
And the diabetes number is lower, at 20.8%. That is expected. People with type 2 diabetes consistently lose less weight on these drugs than people without it. Our comparison of the three GLP-1 compounds covers where that pattern comes from.
When will retatrutide be available?
Submitting a Biologics License Application is the beginning of the review, not the end. Standard FDA review runs around ten to twelve months from acceptance. Priority review, if granted, runs about six.
So a first-quarter 2027 submission points at an approval decision somewhere between late 2027 and mid 2028, assuming no complete response letter, no request for additional data and no manufacturing hold. Any of those adds months.
Then there is launch. Approval is not availability. Pricing gets set afterward, and supply has been a genuine constraint for both competitors that came before it.
So a prescription in a pharmacy is realistically 2028, and the confident 2027 dates circulating describe the filing and not the drug.
Is retatrutide a drug or a biologic, and does that change the date?
It is unsettled in federal court. It matters less for the date than for what comes after it.
Lilly's July 2026 release names the application type: the company says it is completing the manufacturing data package "required for a Biologics License Application (BLA)" and plans to submit retatrutide in the first quarter of 2027 for US approval.[^4]
The FDA has already decided retatrutide is not a biologic. Its rule defines a protein as any "alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size", and it reads "alpha" as governing every unit in that count. Counted that way, retatrutide has 40 alpha amino acids and one that is not. That leaves it at the line, not past it. Lilly counts 41 and says the molecule qualifies.[^5]
Judge Tanya Walton Pratt heard both questions in the Southern District of Indiana and split them on September 30, 2025. She upheld the agency on the protein rule. She went the other way on whether retatrutide is at least "analogous" to a protein, finding that the FDA's reading takes "analogous product" out of the statute, and sent that question back to the agency.[^6] Lilly appealed. The Seventh Circuit heard argument on September 24, 2026 and has not ruled.[^7]
The appeal might not settle it. The FDA argues the appeal is not properly before the court. So does the Outsourcing Facilities Association, which speaks for compounders.[^8] A ruling on that point alone would leave things where they sit now: one question decided against Lilly, one back with the agency.
What turns on this is price, not the calendar. Reporters covering the case put the gap at twelve years of market protection for a biologic against five for a drug.[^8] Patents usually run longer than both and set the real date, so treat that gap as a direction and not as a year. The rules that let a pharmacy copy an approved drug also do not cover a biologic. Retatrutide cannot be compounded now, because it is not approved. What the case decides is whether that still holds once there is a product.
None of this moves the date Lilly has given. It decides what the market looks like on the far side of it.
Does this change anything if you are buying it now?
Almost nothing in the short term, and something worth thinking about in the longer term.
Retatrutide is not approved anywhere. Every vial on the market is research-labelled material of unverified provenance. Our guide on what research use only actually means covers what that label does, and neither is changed by an approval timeline. Sellers have also started numbering past it, and our piece on what GLP-4 actually is covers what turns up under that name.
What the timeline does change is the calculation about waiting. Somebody weighing a grey-market vial against an approved product was previously choosing between now and an unknown date. That unknown is now bounded, and it is roughly eighteen months to two years.
Approval will not end the gray market. Semaglutide is approved, widely prescribed, and has one of the largest unapproved markets of any drug in modern history, for reasons our guide on what peptide therapy costs sets out in detail. The same will happen here.
And the trial doses are public now. TRIUMPH-1 used 12 mg as its top dose over a long titration. Protocols circulating for the research version are not derived from that, and our guide on how long peptides take to work covers why a schedule that resembles a trial is not the same as being one.
Three regulatory stories are running at once. Our coverage of the July 2026 compounding vote and our preview of the February 2027 panel track the other two, and all three are moving on different timetables.
What to watch
CagriSema is the other late-stage obesity program already before the FDA. Our report on what the other program reported covers its direct loss to tirzepatide and why the filing remains unaffected.
TRIUMPH-5
The head-to-head against tirzepatide has completed enrollment and has not reported.[^9] It is the trial that answers whether a triple agonist beats a dual one in practice, instead of across separate studies.
TRIUMPH-Outcomes
A cardiovascular and renal trial of roughly ten thousand people, running for years. Outcomes data is what moves a weight-loss drug from cosmetic to cardiometabolic in prescribing terms, and it is what earned semaglutide its expanded label.
The submission itself
Until a BLA is filed, Q1 2027 is a plan, and plans move.
Safety signals in the full publications
Topline results are press releases. The peer-reviewed papers carry the adverse event tables, and three are now out: TRANSCEND-T2D-1, TRIUMPH-1 and TRIUMPH-2. The phase 2 data included a heart rate increase that will get scrutiny at review.
Is there a safety concern with retatrutide?
One signal is worth understanding before the review starts, because it is the thing most likely to shape the label.
Phase 2 reported an increase in heart rate on retatrutide.[^2] Modest increases in heart rate appear across this whole drug class, and the question at review is always whether the size and duration of the change matter over years rather than months.
That question gets answered by outcomes data and not by weight trials, which is why TRIUMPH-Outcomes exists and why it enrolls around ten thousand people over several years.[^9] Weight loss trials are not designed or powered to detect a cardiovascular harm, and they are not designed to detect a cardiovascular benefit either.
None of that is a prediction of trouble. It is the specific thing to look for in the full publications, three of which are now out, since topline press releases do not carry adverse event tables and the papers do.
There is also the question of what is not being measured in the trials, since the program records metabolic endpoints and nothing about mood or reward.
Where this stops being useful
Whether retatrutide will be approved. Filing is the start of a review, and complete response letters happen to good drugs.
What it will cost. Nothing about pricing has been announced and the two comparable drugs launched at list prices that few people paid.
Whether it is better than what exists. TRIUMPH-5 will answer part of that question once it reports.
For the market as it stands now, see the retatrutide buying guide.
Common questions
Is retatrutide FDA approved?
No. Lilly has said it plans to submit a Biologics License Application in the first quarter of 2027. Nothing has been submitted and no decision date exists.
When will retatrutide be available?
Realistically 2028. A Q1 2027 filing plus a standard ten to twelve month review points at a decision in late 2027 or 2028, and approval is followed by launch, pricing and supply.
What did the pivotal trial show?
TRIUMPH-1 reported 28.3% weight loss at 80 weeks across 2,339 participants with obesity and without diabetes, with a higher figure in the longer extension.
Why is the diabetes number lower?
People with type 2 diabetes consistently lose less weight on these drugs than people without it. TRIUMPH-2 reported 20.8%, and that pattern holds across the class.
Does this make the research version safer to buy?
No. A filing timeline changes nothing about what is in an unapproved vial. Every vial on the market is still research-labelled material of unverified origin, and our guide on vetting a vendor covers the only checks available.
Will approval end the gray market?
It did not for semaglutide, which is approved, widely prescribed, and still has one of the largest unapproved markets of any drug. Cost and access are the reasons, and neither is solved by approval.
What is TRIUMPH-5?
The head-to-head trial against tirzepatide. It has completed enrollment and has not reported, and it is the study that answers whether the triple agonist actually outperforms the dual one.
Why does the sleep apnea indication matter?
Coverage. Insurers frequently refuse a prescription written for weight alone and frequently pay for the same drug against a named condition. Tirzepatide's sleep apnea approval in late 2024 changed who could obtain it without changing the drug.
Is there a safety concern?
Phase 2 reported an increase in heart rate, which appears across this drug class. Whether it matters over years is what the cardiovascular outcomes trial exists to answer, and a weight trial cannot.
Could the timeline slip?
Yes. A filing plan is not a submission, and review can be extended by a request for more data or a manufacturing issue. Q1 2027 is the earliest reasonable date rather than a fixed one.
Is retatrutide a drug or a biologic?
The FDA has determined it is a drug, not a biologic, because its rule counts only alpha amino acids and retatrutide reaches 40 of them rather than more than 40. Lilly counts 41 and disagrees. A district court upheld the FDA on that point in September 2025 and sent a second question back to the agency. The Seventh Circuit heard argument on September 24, 2026 and has not ruled.
Does the classification change when I could get it?
Not the submission date, which Lilly has put at the first quarter of 2027. It changes how long the product would have the market to itself afterward, and whether a pharmacy could ever make a copy of it.
Sources
[^1]: Eli Lilly and Company. Form 8-K, second quarter 2026 results, filed with the US Securities and Exchange Commission. Regulatory filing, read at source. States that pipeline highlights included positive data from three additional phase 3 trials of retatrutide in obesity, that the clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, and that the company plans to submit a Biologics License Application to the US FDA in the first quarter of 2027. This is the primary source for the filing window and it should be preferred over any press coverage of the same announcement.
[^2]: Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023. Peer-reviewed phase 2 randomised trial. 338 participants, 48 weeks, reported 24.2% weight loss at the 12 mg dose, and reported an increase in heart rate that will be examined again at review. See also our comparison of the three GLP-1 compounds, which covers the distinction between the completer and intention-to-treat figures from this trial.
[^3]: TRIUMPH phase 3 program topline results. Company announcements and trade press reporting, compiled across four independent sources that agree on the figures. TRIUMPH-4 reported December 2025 in obesity with knee osteoarthritis, 28.7% weight loss. TRANSCEND-T2D-1 reported March 2026, A1C reduction of 1.7 to 2.0% and 16.8% weight loss. TRIUMPH-1, the pivotal obesity registration trial, reported 21 May 2026 with 28.3% weight loss at 80 weeks in 2,339 participants and a higher figure in the 104-week extension. TRIUMPH-2 and TRIUMPH-3 reported 23 July 2026 with 20.8% and 22.6% weight loss respectively. Three have since been published in full: TRANSCEND-T2D-1 in The Lancet in June 2026, TRIUMPH-1 in the New England Journal of Medicine in September 2026, and TRIUMPH-2 in The Lancet in September 2026 (2026;407:2402-2413). TRIUMPH-3 and TRIUMPH-4 remain topline announcements, and their papers should be substituted as they appear.
[^4]: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Eli Lilly and Company, news release, July 23, 2026. investor.lilly.com. Read at source. The subheading reads "Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027". The body says Lilly "is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package" "required for a Biologics License Application (BLA)" and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval". Chief executive Kenneth Custer is quoted saying the company "now ha[s] the clinical data package to support global submissions for retatrutide" as a potential treatment for "obesity, knee osteoarthritis pain, and obstructive sleep apnea".
[^5]: Eli Lilly & Co. v. Kennedy. Food and Drug Law Institute, June 2026. fdli.org. Read at source, as legal analysis rather than a party filing. The FDA's protein definition is given as "any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size". The agency counted 40 alpha amino acids plus one non-alpha amino acid, 8-amino-3,6-dioxaoctanoic acid (ADO), and concluded retatrutide is "not an alpha amino acid polymer with a specific defined sequence greater than 40 amino acids in size". Lilly describes the molecule as 41 amino acids in total, a 39-residue alpha backbone plus a two-residue chain of gamma-glutamate and ADO, and argues every amino acid should count.
[^6]: Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503-TWP-KMB (S.D. Ind. September 30, 2025), Hon. Tanya Walton Pratt. courtlistener.com. Read via a reproduction of the court's own opinion on CourtListener; the court's own docket could not be opened for this page. The court granted and denied both sides' cross-motions in part. It upheld the FDA's conclusion that retatrutide is not a "protein" under the regulatory definition. It held that the agency's refusal to treat retatrutide as "analogous" to a protein was not in accordance with law, because the bright-line approach "effectively reads 'analogous product' out of the statute", and the disposition states that this decision is "VACATED and REMANDED to the agency for further consideration".
[^7]: Eli Lilly and Company v. Robert Kennedy, Jr., No. 26-1301, oral argument calendar. United States Court of Appeals for the Seventh Circuit. media.ca7.uscourts.gov. Read at source. The court's own listing gives a Date Argued of 09/24/2026 and links argument audio. No appellate opinion was found as of October 15, 2026. The panel is not named on that listing.
[^8]: Basile J. Can a new weight loss treatment escape the legal and regulatory thicket? Reason, September 10, 2026. reason.com. Read at source. Reports that the FDA disputes whether the appeal is properly before the court and that the Outsourcing Facilities Association argues it is not "properly before the Court"; that biologics carry twelve years of exclusivity against five for new drugs; and that a biologic designation "could protect Lilly from compounding competition and provide longer exclusivity". The twelve-and-five figures are this outlet's framing of the statutory periods, not a quotation of either statute, and this page presents them as such.
[^9]: TRIUMPH-5 and TRIUMPH-Outcomes trial status. ClinicalTrials.gov registry entries, reported across secondary sources as active. TRIUMPH-5 is a head-to-head comparison against tirzepatide with a body weight primary endpoint. TRIUMPH-Outcomes is a multi-year cardiovascular and renal outcomes trial enrolling approximately 10,000 participants.